Effects of ivabradine on cardiovascular events in patients with stable coronary artery disease and left ventricular systolic dysfunction. A three-year randomised double-blind placebo-controlled international multicentre study. - BEAUTIF

Institut de Recherches Internationales0 个研究点目标入组 9,650 人开始时间: 2005年2月23日最近更新: 2019年11月25日

适应症

试验速览

暂无简介。

•The main inclusion criteria will be:
•(1) history of coronary artery disease documented on a coronary angiography or by a previous myocardial infarction or a coronary revascularisation and
•(2) left ventricular systolic dysfunction defined as a left ventricular ejection fraction equal to 39% or lower on a two-dimensional echocardiography and a left ventricular dilatation defined as an echocardiographically measured short-axis internal dimension greater than 56 millimetres and
•(3) sinus rhythm and resting heart rate equal to or higher than 60 beats per minute and
•(4) informed consent obtained.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•The main exclusion criteria will be:
•(1) unstable cardiovascular condition
•(2) severe congestive heart failure (class IV of the classification of the New-York Heart Association)
•(3) contra-indications to the administration of ivabradine.

发起方

Institut de Recherches Internationales